FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W157322695> ?p ?o ?g. }

• W157322695 endingPage "751" @default.
• W157322695 startingPage "751" @default.
• W157322695 abstract "751 Background: PEP02 is a highly stable nanoliposomal irinotecan. This randomized non-comparative phase II (PEPCOL) study evaluated the efficacy and safety of PEP02 (MM-398) or irinotecan in combination with LV/5-FU in the second-line treatment of metastatic colorectal cancer (mCRC). (EudraCT 2010-020468-39A, NCT01375816). Methods: Patients with unresectable mCRC who had failed one prior oxaliplatin-based first-line therapy were randomly assigned to FUPEP (PEP02 80 mg/m² d1, folinic acid (FA) 400 mg/m² d1, 5-FU 2,400 mg/m² d1-2) or FOLFIRI (FOLFIRI1: irinotecan 180 mg/m² d1, FA 400 mg/m² d1, 5-FU bolus 400 mg/m² d1, 5-FU infusion 2,400 mg/m² d1-2; or modified FOLFIRI3: irinotecan 90 mg/m² d1 and 3, FA 400 mg/m² d1, 5-FU infusion 2,400 mg/m² d1-2). Bevacizumab q2w (5 mg/kg) was allowed in both arms as of June 2012 (TML study report). The primary endpoint was the objective tumor response (OR). Results: Fifty-five patients were randomized (FUPEP, n=28; FOLFIRI, n=27). In the evaluable population (n=50), OR rate were 16.7% (n=4/24) and 11.5% (n=3/26) in the FUPEP and the FOLFIRI arms, respectively. Most common grade 3-4 adverse events reported in the respective FUPEP and the FOLFIRI arms were diarrhea (21% vs 33%), neutropenia (11% vs 30%), mucositis (11% vs 11%), and alopecia (G2: 25% vs 26%). Conclusions: FUPEP regimen exhibits promising tumor response and safety profile, and can be combined with bevacizumab, for oxaliplatin-pretreated patients. Hence PEP02 (MM-398) may provide a new second-line treatment option for mCRC. Based on the safety profile of the FUPEP regimen in this PEPCOL study, it was added as the third arm to the positive phase III metastatic pancreatic cancer (NAPOLI-1) study. Clinical trial information: NCT01375816." @default.
• W157322695 created "2016-06-24" @default.
• W157322695 creator A5002063921 @default.
• W157322695 creator A5013525685 @default.
• W157322695 creator A5017450295 @default.
• W157322695 creator A5027487921 @default.
• W157322695 creator A5028514396 @default.
• W157322695 creator A5028595536 @default.
• W157322695 creator A5037046128 @default.
• W157322695 creator A5040827219 @default.
• W157322695 creator A5042489163 @default.
• W157322695 creator A5054670872 @default.
• W157322695 creator A5054891546 @default.
• W157322695 creator A5064556770 @default.
• W157322695 creator A5067073528 @default.
• W157322695 creator A5069277900 @default.
• W157322695 creator A5079480540 @default.
• W157322695 creator A5082387489 @default.
• W157322695 creator A5084981411 @default.
• W157322695 date "2015-01-20" @default.
• W157322695 modified "2023-10-03" @default.
• W157322695 title "PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer—A GERCOR Study." @default.
• W157322695 doi "https://doi.org/10.1200/jco.2015.33.3_suppl.751" @default.
• W157322695 hasPublicationYear "2015" @default.
• W157322695 type Work @default.
• W157322695 sameAs 157322695 @default.
• W157322695 citedByCount "1" @default.
• W157322695 countsByYear W1573226952018 @default.
• W157322695 crossrefType "journal-article" @default.
• W157322695 hasAuthorship W157322695A5002063921 @default.
• W157322695 hasAuthorship W157322695A5013525685 @default.
• W157322695 hasAuthorship W157322695A5017450295 @default.
• W157322695 hasAuthorship W157322695A5027487921 @default.
• W157322695 hasAuthorship W157322695A5028514396 @default.
• W157322695 hasAuthorship W157322695A5028595536 @default.
• W157322695 hasAuthorship W157322695A5037046128 @default.
• W157322695 hasAuthorship W157322695A5040827219 @default.
• W157322695 hasAuthorship W157322695A5042489163 @default.
• W157322695 hasAuthorship W157322695A5054670872 @default.
• W157322695 hasAuthorship W157322695A5054891546 @default.
• W157322695 hasAuthorship W157322695A5064556770 @default.
• W157322695 hasAuthorship W157322695A5067073528 @default.
• W157322695 hasAuthorship W157322695A5069277900 @default.
• W157322695 hasAuthorship W157322695A5079480540 @default.
• W157322695 hasAuthorship W157322695A5082387489 @default.
• W157322695 hasAuthorship W157322695A5084981411 @default.
• W157322695 hasConcept C121608353 @default.
• W157322695 hasConcept C126322002 @default.
• W157322695 hasConcept C168563851 @default.
• W157322695 hasConcept C197934379 @default.
• W157322695 hasConcept C203092338 @default.
• W157322695 hasConcept C2776694085 @default.
• W157322695 hasConcept C2776705615 @default.
• W157322695 hasConcept C2777063308 @default.
• W157322695 hasConcept C2777802072 @default.
• W157322695 hasConcept C2778496288 @default.
• W157322695 hasConcept C2779804826 @default.
• W157322695 hasConcept C2780259306 @default.
• W157322695 hasConcept C2780456651 @default.
• W157322695 hasConcept C2780962732 @default.
• W157322695 hasConcept C2781413609 @default.
• W157322695 hasConcept C2908647359 @default.
• W157322695 hasConcept C31760486 @default.
• W157322695 hasConcept C526805850 @default.
• W157322695 hasConcept C71924100 @default.
• W157322695 hasConcept C90924648 @default.
• W157322695 hasConcept C99454951 @default.
• W157322695 hasConceptScore W157322695C121608353 @default.
• W157322695 hasConceptScore W157322695C126322002 @default.
• W157322695 hasConceptScore W157322695C168563851 @default.
• W157322695 hasConceptScore W157322695C197934379 @default.
• W157322695 hasConceptScore W157322695C203092338 @default.
• W157322695 hasConceptScore W157322695C2776694085 @default.
• W157322695 hasConceptScore W157322695C2776705615 @default.
• W157322695 hasConceptScore W157322695C2777063308 @default.
• W157322695 hasConceptScore W157322695C2777802072 @default.
• W157322695 hasConceptScore W157322695C2778496288 @default.
• W157322695 hasConceptScore W157322695C2779804826 @default.
• W157322695 hasConceptScore W157322695C2780259306 @default.
• W157322695 hasConceptScore W157322695C2780456651 @default.
• W157322695 hasConceptScore W157322695C2780962732 @default.
• W157322695 hasConceptScore W157322695C2781413609 @default.
• W157322695 hasConceptScore W157322695C2908647359 @default.
• W157322695 hasConceptScore W157322695C31760486 @default.
• W157322695 hasConceptScore W157322695C526805850 @default.
• W157322695 hasConceptScore W157322695C71924100 @default.
• W157322695 hasConceptScore W157322695C90924648 @default.
• W157322695 hasConceptScore W157322695C99454951 @default.
• W157322695 hasIssue "3_suppl" @default.
• W157322695 hasLocation W1573226951 @default.
• W157322695 hasOpenAccess W157322695 @default.
• W157322695 hasPrimaryLocation W1573226951 @default.
• W157322695 hasRelatedWork W157322695 @default.
• W157322695 hasRelatedWork W1970391226 @default.
• W157322695 hasRelatedWork W2032188922 @default.
• W157322695 hasRelatedWork W2135626946 @default.
• W157322695 hasRelatedWork W2171576276 @default.
• W157322695 hasRelatedWork W2503036974 @default.

• next